Vanda Pharmaceuticals (VNDA)
(Delayed Data from NSDQ)
$5.32 USD
+0.05 (0.95%)
Updated Jul 9, 2024 04:00 PM ET
After-Market: $5.32 0.00 (0.00%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMEarnings News For VNDA
-
Vanda: Q1 Earnings Snapshot
-
Vanda Pharmaceuticals Reports First Quarter 2024 Financial Results
-
Vanda (VNDA) to Report Q1 Earnings: What's in the Cards?
-
Vanda: Q4 Earnings Snapshot
-
Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results
-
Vanda Pharmaceuticals (VNDA) Reports Break-Even Earnings for Q3
-
Vanda Pharmaceuticals Reports Third Quarter 2023 Financial Results
-
Vanda: Q2 Earnings Snapshot
-
Vanda Pharmaceuticals Reports Second Quarter 2023 Financial Results
-
Vanda: Q1 Earnings Snapshot
-
Vanda Pharmaceuticals Reports First Quarter 2023 Financial Results
-
Vanda: Q4 Earnings Snapshot
-
Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results
-
Vanda Pharmaceuticals (VNDA) Lags Q3 Earnings and Revenue Estimates
-
Vanda: Q3 Earnings Snapshot
-
Vanda Pharmaceuticals Reports Third Quarter 2022 Financial Results
-
Vanda Pharmaceuticals (VNDA) Q2 Earnings and Revenues Miss Estimates
-
Vanda: Q2 Earnings Snapshot
-
Vanda Pharmaceuticals Reports Second Quarter 2022 Financial Results
-
Vanda Pharmaceuticals (VNDA) Reports Q1 Loss, Tops Revenue Estimates
-
Earnings Preview: Vanda Pharmaceuticals (VNDA) Q1 Earnings Expected to Decline
-
Vanda Pharmaceuticals (VNDA) Misses Q3 Earnings and Revenue Estimates
-
Vanda Pharmaceuticals (VNDA) Earnings Expected to Grow: What to Know Ahead of Q3 Release
-
Vanda Pharmaceuticals (VNDA) Matches Q2 Earnings Estimates
-
Vanda Pharmaceuticals (VNDA) Surpasses Q1 Earnings and Revenue Estimates